Fungal biosynthetic pathway enzymes and other intracellular antifungal targets

Fungal biosynthetic pathway enzymes and other intracellular antifungal targets comprise a diverse group of proteins and metabolic processes essential for fungal viability and structural integrity [1]. This category includes enzymes in the ergosterol biosynthesis pathway, such as lanosterol 14-alpha-demethylase (CYP51) and squalene epoxidase, which are critical for maintaining the fungal cell membrane [1][3]. It also encompasses enzymes responsible for the synthesis of cell wall components, specifically beta-1,3-glucan synthase and chitin synthase, which provide osmotic stability and structural support [2]. Intracellular targets also include the machinery for nucleic acid synthesis, such as thymidylate synthase, and protein synthesis, as well as structural proteins like beta-tubulin involved in mitosis [1][4]. Antifungal drugs such as azoles, allylamines, echinocandins, and antimetabolites exert their effects by inhibiting these specific targets, leading to fungistatic or fungicidal outcomes [3]. While these targets are chosen for their divergence from human biology, challenges such as cross-reactivity with human cytochrome P450 enzymes and the rapid emergence of multi-drug resistance remain significant clinical hurdles [4].

Other names

Intracellular antifungal targetsFungal biosynthetic enzymesFungal metabolic targetsFungal intracellular enzymes

Inhibition of ergosterol biosynthesis (e.g., CYP51, squalene epoxidase), inhibition of cell wall synthesis (e.g., 1,3-beta-D-glucan synthase), inhibition of nucleic acid synthesis, and disruption of microtubule assembly.